PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14619337-9	2003	Inhibition of CysLTs by 10 microM of montelukast was noted in 5 patients with RW and in 10 patients with M. Levels of RANTES in some patients were increased by both allergens without consistent inhibitory effects of montelukast.	montelukast	37-48	C-C motif chemokine ligand 5	Homo sapiens	118-124	
24080250-9	2013	Montelukast significantly suppressed the release of IL-8 (p = 0.016), IL-6 (p = 0.006), RANTES (p = 0.002) and IFN-gamma (p = 0.046), in a dose dependent manner in unstimulated cultures but not in those stimulated with IL-1/TNF.	montelukast	0-11	C-C motif chemokine ligand 5	Homo sapiens	88-94	
24080250-10	2013	Withdrawal of Montelukast treatment, was associated with increased IL-8 and RANTES secretion in unstimulated nasal AEC cultured from subjects with asthma and allergic rhinitis but not with asthma alone.	montelukast	14-25	C-C motif chemokine ligand 5	Homo sapiens	76-82	
24080250-11	2013	CONCLUSIONS: Montelukast treatment for asthma symptoms reversibly suppresses nasal AEC release of pro-inflammatory mediators (i.e. IL-8 and RANTES) but only in those cells cultured from subjects with concomitant allergic rhinitis.	montelukast	13-24	C-C motif chemokine ligand 5	Homo sapiens	140-146